The study of fosaprepitant in the prevention of chemotherapy induced nausea and vomiting in patients with gynecologic cancer undergoing the combination therapy of Taxens and carboplatin.

The study of fosaprepitant in the prevention of chemotherapy induced nausea and vomiting in patients with gynecologic cancer undergoing the combination therapy of Taxens and carboplatin. - The study of fosaprepitant in the prevention of chemotherapy induced nausea and vomiting in patients with gynecologic cancer undergoing the combination therapy of Taxens and carboplatin.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000017804

Enrollment

Registered

2015-06-05

Start date

2013-07-03

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical cancer, Endometrial cancer, Ovarian cancer, Fallopian tube cancer, and peritoneal cancer

Interventions

fosaprepitant for the patients who were not fully prevented from CINV with the combination of palonosetron and dexamethasone.

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1)Gynecological cancer patients who underwent the combination therapy of carboplatin and Taxens. 2)The patients who can list her symptom diary appropriately. 3)The patients who agreed participation of this study by written documents.

Exclusion criteria

Exclusion criteria: 1)The patient who is complicated with a serious liver damage or a renal damage. 2)A pregnant woman and the patient who may be pregnant now. 3)A patient with past hypersensitivity of fosaprepitant and/or ingredient of aprepitant. 4)A patient using Pimozide. 5)A patient using steroids. 6)Patients who were determined unsuitable for this study by medical doctors.

Design outcomes

Primary

Measure	Time frame
the proportion of the patients with a complete response (CR, which was defined as no episodes of vomiting and no rescue therapy for nausea).	—

Countries

Japan

Contacts

Public ContactAkira Kurosaki

Saitama Medical University International Medical Center Gynecologic Oncology

akirak@saitama-med.ac.jp+81-42-984-4111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026